Nucleoside reverse transcriptase inhibitors and HIV mutagenesis

Journal of Antimicrobial Chemotherapy

Volumn 52, Issue 4, 2003, Pages 547-550

  Jewell, Nancy A ^a   Chen, Renxiang ^a   Raices, Raquel ^a   Mansky, Louis M ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Evolution; Mutagenesis; NRTIs; Resistance; Retrovirus

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; BETA GALACTOSIDASE; CEFOTAXIME; DIDANOSINE; HYDROXYUREA; LAMIVUDINE; PROTEINASE INHIBITOR; RIBAVIRIN; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; STREPTOMYCIN; THYMIDINE; TIOGUANINE; VANCOMYCIN; ZALCITABINE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG TARGETING; ESCHERICHIA COLI; HELICOBACTER PYLORI; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTAGENESIS; NONHUMAN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; VIRUS MUTATION; VIRUS REPLICATION;

ANIMALS; DRUG RESISTANCE, MICROBIAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTAGENESIS; NUCLEOSIDES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0141963105     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg387     Document Type: Article

References (18)

1. Mansky, L. M. & Bernard, L. C. (2000). 3′-Azido-3′-deoxythymidine (AZT) and AZT-resistant reverse transcriptase can increase the in vivo mutation rate of human immunodeficiency virus type 1. Journal of Virology 74, 9532-9.
2. Mansky, L. M., Le Rouzic, E., Benichou, S. et al. (2003). Influence of reverse transcriptase variants, drugs, and Vpr on human immunodeficiency virus type 1 mutant frequencies. Journal of Virology 77, 2071-80.
3. Mansky, L. M. (2003). Mutagenic outcome of combined antiviral drug treatment during human immunodeficiency virus type 1 replication. Virology 307, 1116-21.
4. Mansky, L. M., Pearl, D. K. & Gajary, L. C. (2002). Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequencies. Journal of Virology 76, 9253-9.
5. Drake, J. W. & Holland, J. J. (1999). Mutation rates among RNA viruses. Proceedings of the National Academy of Sciences, USA 96, 13910-3.
6. Crotty, S., Maag, D., Arnold, J. J. et al. (2000). The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nature Medicine 6, 1375-9.
7. Ruiz-Jarabo, C. M., Ly, C., Domingo, E. et al. (2003). Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology 308, 37-47.
8. Loeb, L. A., Essigmann, J. M., Kazazi, F. et al. (1999). Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proceedings of the National Academy of Sciences, USA 96, 1492-7.
9. Bjedov, I., Tenaillon, O., Gerard, B. et al. (2003). Stress-induced mutagenesis in bacteria. Science 300, 1404-9.
10. Martinez, J. L. & Baquero, F. (2000). Mutation frequencies and antibiotic resistance. Antimicrobial Agents and Chemotherapy 44, 1771-7.
11. Giraud, A., Matic, I., Radman, M. et al. (2002). Mutator bacteria as a risk factor in treatment of infectious diseases. Antimicrobial Agents and Chemotherapy 46, 863-5.
12. Gerrish, P. J. & Garcia-Lerma, J. G. (2003). Mutation rate and the efficacy of antimicrobial drug treatment. Lancet Infectious Diseases 3, 28-32.
13. Boshoff, H. I., Reed, M. B., Barry, C. E. et al. (2003). DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis. Cell 113, 183-93.
14. Ren, L., Rahman, M. S. & Humayun, M. Z. (1999). Escherichia coli cells exposed to streptomycin display a mutator phenotype. Journal of Bacteriology 181, 1043-4.
15. Schaaff, F., Reipert, A. & Bierbaum, G. (2002). An elevated mutation frequency favors development of vancomycin resistance in Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 46, 3540-8.
16. Negri, M.-F., Morosini, M.-I., Baquero, M.-R. et al. (2002). Very low cefotaxime concentrations select for hypermutable Streptococcus pneumoniae populations. Antimicrobial Agents and Chemotherapy 46, 528-30.
17. Oliver, A., Canton, R., Campo, P. et al. (2000). High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288, 1251-4.
18. Bjorkholm, B., Sjolund, M., Falk, P. G. et al. (2001). Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori. Proceedings of the National Academy of Sciences, USA 98, 14607-12.